
On Thursday, Novo Nordisk annouced that it is acquiring the US-based biotech company Dicerna for USD 3.3bn.
The Dicerna acquisition has sent a big check to diabetes competitor Eli Lilly, which has several development partnerships with Dicerna.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app